Ipilimumab
Metastatic Malignant Neoplasm In The Colon
Explore 65 assets in Metastatic Malignant Neoplasm In The Colon →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07587827CT.gov Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | — | Not Yet Recruiting | — | — | — |
NCT05310643CT.gov Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | — | Recruiting | — | — | — |
NCT04730544CT.gov Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | — | Active Not Recruiting | — | — | — |
NCT04575922CT.gov Nivolumab+Ipilimumab+RT in MSS mCRC | — | Unknown | — | — | — |
NCT04362839CT.gov Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT04008030CT.gov A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | — | Active Not Recruiting | — | — | — |
NCT03982121CT.gov Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy | — | Withdrawn | — | — | — |
NCT03832621CT.gov NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03373188CT.gov VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer | — | Completed | — | — | — |
NCT03350126CT.gov iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab | — | Active Not Recruiting | — | — | — |
Show 1 more trialShow fewer
NCT04721301CT.gov Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Malignant Neoplasm In The Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | GERCOR - Multidisciplinary Oncology Cooperative Group | P2 | B · 56 |
| Binimetinib | Pierre Fabre Medicament | P3 | BB |
| Irinotecan | Oncolytics Biotech | P4 | BB |
| Aflibercept | Sanofi | P3 | BB |
| Adriamycin | Northwell Health | P4 | B |
| Durvalumab | University of Iowa | P2 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Centre Georges Francois Leclerc | P2 | B |
| Famitinib | Jiangsu HengRui Medicine Co., Ltd. | P3 | B |
| Tivantinib | Armando Santoro, MD | P2 | B |
+42 more in the Metastatic Malignant Neoplasm In The Colon cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ipilimumab in Metastatic Malignant Neoplasm In The Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-metastatic-malignant-neoplasm-in-the-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →